

Financial news for FPRX dated on 2020-05-29: 65 Biggest Movers From Yesterday

Financial news for FPRX dated on 2020-05-19: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for FPRX dated on 2020-05-07: Five Prime Therapeutics Q1 EPS \$(0.570) Beats \$(0.670) Estimate

Financial news for FPRX dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for FPRX dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for FPRX dated on 2020-04-14: Five Prime Therapeutics Reports William Ringo Will No Longer Be CEO, Will Remain As Chair; Names Tom Civik Replacement As CEO

Financial news for FPRX dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for FPRX dated on 2020-03-13: Stocks That Hit 52-Week Lows On Friday

Financial news for FPRX dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for FPRX dated on 2020-03-11: Stocks That Hit 52-Week Lows On Wednesday

Financial news for FPRX dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for FPRX dated on 2020-03-02: 140 Biggest Movers From Friday

Financial news for FPRX dated on 2020-02-28: 50 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for FPRX dated on 2020-02-28: JP Morgan Downgrades Five Prime Therapeutics to Underweight

Financial news for FPRX dated on 2020-02-27: Five Prime Therapeutics Q4 EPS \$(0.89) Beats \$(0.97) Estimate, Sales \$3.21M Miss \$4.65M Estimate

Financial news for FPRX dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lilly, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for FPRX dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for FPRX dated on 2020-02-20: 78 Biggest Movers From Yesterday

Financial news for FPRX dated on 2020-02-19: 51 Stocks Moving In Wednesday's Mid-Day Session

Financial news for FPRX dated on 2020-02-19: Benzinga's Top Upgrades, Downgrades For February 19, 2020

Financial news for FPRX dated on 2020-02-19: 10 Biggest Price Target Changes For Wednesday

Financial news for FPRX dated on 2020-02-19: Wedbush Downgrades Five Prime Therapeutics to Neutral, Lowers Price Target to \$5

Financial news for FPRX dated on 2020-02-18: Five Prime Therapeutics Reports Phase 2 Trial Of Cabiralizumab Plus Opdivo Did Not Meet Primary Endpoint

Financial news for FPRX dated on 2020-02-04: 85 Biggest Movers From Yesterday

Financial news for FPRX dated on 2020-01-22: 98 Biotechnology Stocks Moving In Wednesday's Session

Financial news for FPRX dated on 2020-01-22: 116 Healthcare Stocks Moving In Wednesday's Session

Financial news for FPRX dated on 2020-01-22: 82 Biggest Movers From Yesterday

Financial news for FPRX dated on 2020-01-07: 50 Biggest Movers From Yesterday

Financial news for FPRX dated on 2019-12-27: Five Prime Therapeutics 13D From Biotech Value Fund Shows 21.4% Stake

Financial news for FPRX dated on 2019-12-26: Five Prime Reports Founder And Board Member, Rusty Williams To Resign

Financial news for FPRX dated on 2019-12-12: 70 Biggest Movers From Yesterday

Financial news for FPRX dated on 2019-11-26: 45 Biggest Movers From Yesterday

Financial news for FPRX dated on 2019-11-25: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for FPRX dated on 2019-11-20: The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

Financial news for FPRX dated on 2019-11-19: Stocks That Hit 52-Week Lows On Tuesday

Financial news for FPRX dated on 2019-11-19: The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

Financial news for FPRX dated on 2019-11-06: Five Prime Therapeutics Q3 EPS \$(1.03) Misses \$(0.95) Estimate, Sales \$2.8M Miss \$5.23M Estimate

Financial news for FPRX dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for FPRX dated on 2019-10-29: 46 Biggest Movers From Yesterday

Financial news for FPRX dated on 2019-10-28: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for FPRX dated on 2019-10-11: The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

Financial news for FPRX dated on 2019-10-10: Five Prime Therapeutics Shares Resume Trade, Not Yet Seeing Updated Last Price

Financial news for FPRX dated on 2019-10-10: Five Prime Therapeutics, Aclaris Shares To Resume Trade At 4:30 p.m. EDT

Financial news for FPRX dated on 2019-10-10: Five Prime Therapeutics Reaffirms FY19 Cash Guidance \$148M-\$153M In Cash

Financial news for FPRX dated on 2019-10-10: Five Prime Sees Restructuring Resulting In \$20M In Annualized Cost Savings

Financial news for FPRX dated on 2019-10-10: Five Prime Therapeutics Reports Corporate Restructuring To Extend Co.'s Cash Runway Without Impacting, Delaying Data Timelines Clinicals Programs

Financial news for FPRX dated on 2019-10-10: Five Prime Therapeutics Shares Halted News Pending

Financial news for FPRX dated on 2019-10-10: 50 Biggest Movers From Yesterday

Financial news for FPRX dated on 2019-10-09: 28 Stocks Moving In Wednesday's Mid-Day Session

Financial news for FPRX dated on 2019-10-02: The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data

Financial news for FPRX dated on 2019-10-01: Stocks That Hit 52-Week Lows On Tuesday

Financial news for FPRX dated on 2019-10-01: Benzinga's Top Upgrades, Downgrades For October 1, 2019

Financial news for FPRX dated on 2019-10-01: The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

Financial news for FPRX dated on 2019-10-01: Guggenheim Securities Downgrades Five Prime Therapeutics to Neutral

Financial news for FPRX dated on 2019-09-30: Stocks That Hit 52-Week Lows On Monday

Financial news for FPRX dated on 2019-09-29: The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear

Financial news for FPRX dated on 2019-09-27: The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

Financial news for FPRX dated on 2019-09-27: 50 Biggest Movers From Yesterday

Financial news for FPRX dated on 2019-09-26: The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

Financial news for FPRX dated on 2019-09-25: Stocks That Hit 52-Week Lows On Wednesday

Financial news for FPRX dated on 2019-09-25: The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug

Financial news for FPRX dated on 2019-09-20: The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering

Financial news for FPRX dated on 2019-09-19: Five Prime Therapeutics Names Bill Ringo Interim CEO Succeeding Aron Knickerbocker

Financial news for FPRX dated on 2019-08-07: Five Prime Therapeutics Q2 EPS \$(0.99) Misses \$(0.9) Estimate, Sales \$3.333M May Not Compare To \$7.73M Estimate

Financial news for FPRX dated on 2019-08-05: New 52-Week Lows For Monday Morning

Financial news for FPRX dated on 2019-07-29: 40 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for FPRX dated on 2019-07-25: The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug

Financial news for FPRX dated on 2019-07-23: List of Companies Reaching Yearly Lows Tuesday

Financial news for FPRX dated on 2019-07-10: The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV

Financial news for FPRX dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for FPRX dated on 2019-06-06: The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

Financial news for FPRX dated on 2019-06-04: The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer

Financial news for FPRX dated on 2019-06-04: 66 Biggest Movers From Yesterday

Financial news for FPRX dated on 2019-06-03: 51 Stocks Moving In Monday's Mid-Day Session

Financial news for FPRX dated on 2019-06-03: Five Prime Therapeutics shares are trading lower after Wells Fargo downgraded the company's stock from Outperform to Market Perform and lowered the price target from \$35 to \$10.

Financial news for FPRX dated on 2019-06-03: 5 Biggest Price Target Changes For Monday

Financial news for FPRX dated on 2019-06-03: Benzinga's Top Upgrades, Downgrades For June 3, 2019

Financial news for FPRX dated on 2019-06-03: Wells Fargo Downgrades Five Prime Therapeutics to Market Perform, Lowers Price Target to \$10

Financial news for FPRX dated on 2019-06-01: Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at #ASCO2019; One Patient With Ovarian Cancer Achieved Confirmed Partial

Response With Duration of 6.2 Months

Financial news for FPRX dated on 2019-05-29: Roth Capital Initiates Coverage On Five Prime Therapeutics with Neutral Rating, Announces \$10 Price Target

Financial news for FPRX dated on 2019-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for FPRX dated on 2019-05-10: Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%

Financial news for FPRX dated on 2019-05-08: Five Prime Therapeutics Q1 EPS \$(1.02) Beats \$(1.06) Estimate, Sales \$5.347M Beat \$4.79M Estimate

Financial news for FPRX dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for FPRX dated on 2019-04-12: Guggenheim Initiates Coverage On Five Prime Therapeutics with Buy Rating, Announces \$24 Price Target

Financial news for FPRX dated on 2019-02-26: Five Prime Therapeutics Q4 EPS \$(1.12) Beats \$(1.32) Estimate, Sales \$4M Miss \$8.01M Estimate

Financial news for FPRX dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for FPRX dated on 2019-02-21: Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150

Financial news for FPRX dated on 2019-01-28: 55 Biggest Movers From Friday

Financial news for FPRX dated on 2019-01-18: 48 Biggest Movers From Yesterday

Financial news for FPRX dated on 2019-01-17: Five Prime Therapeutics Highlights Presentation Of Data From Safety Lead-In To Phase 3 FIGHT Trial Of Bemarituzumab At 2019 American Society Of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

Financial news for FPRX dated on 2019-01-17: 34 Stocks Moving In Thursday's Mid-Day Session

Financial news for FPRX dated on 2019-01-17: Five Prime Therapeutics shares are trading higher after Wedbush upgraded the company's stock from Neutral to Outperform.

Financial news for FPRX dated on 2019-01-17: Wedbush Upgrades Five Prime Therapeutics to Outperform

Financial news for FPRX dated on 2019-01-17: The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US

Financial news for FPRX dated on 2019-01-15: 8 Stocks Moving In Tuesday's After-Hours Session

Financial news for FPRX dated on 2019-01-15: Five Prime Sees Ending 2019 With \$148M-\$153M In Cash

Financial news for FPRX dated on 2019-01-15: UPDATE: Five Prime Says Will Eliminate 41 Positions From Workforce, Or About 20% Of Total Headcount

Financial news for FPRX dated on 2019-01-15: Five Prime Reports Will Restructure To Focus On Clinical Development, Later-Stage Research Priorities

Financial news for FPRX dated on 2019-01-13: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for FPRX dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for FPRX dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for FPRX dated on 2018-12-17: Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018

Financial news for FPRX dated on 2018-12-14: Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018

Financial news for FPRX dated on 2018-12-14: The Daily Biotech Pulse: Axovant In-

Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch

Financial news for FPRX dated on 2018-12-14: 51 Biggest Movers From Yesterday

Financial news for FPRX dated on 2018-12-10: 31 Stocks Moving In Monday's Pre-Market Session

Financial news for FPRX dated on 2018-11-14: Five Prime Reports Initiation Of Patient Dosing In Phase 1 Trial Of FPT155

Financial news for FPRX dated on 2018-11-08: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018

Financial news for FPRX dated on 2018-11-08: The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering

Financial news for FPRX dated on 2018-11-06: Five Prime Therapeutics Filing Shows Registration For \$250M Common Stock Offering

Financial news for FPRX dated on 2018-11-06: Five Prime Therapeutics Q3 EPS \$(1.37) Misses \$(1.15) Estimate, Sales \$5.771M Miss \$7.4M Estimate

Financial news for FPRX dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for FPRX dated on 2018-11-05: Five Prime Therapeutics In 8-K Says David Smith To Join Co. As CFO Nov 26

Financial news for FPRX dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for FPRX dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for FPRX dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

Financial news for FPRX dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for FPRX dated on 2018-10-16: Five Prime Therapeutics Initiates Patient Dosing In The Dose Exploration Cohort Of Its Phase 1 Trial Of Novel First-In-Class B7-H4 Antibody FPA150

Financial news for FPRX dated on 2018-09-13: Leerink Swann Reinstates Outperform on Five Prime Therapeutics, Announces \$24

Financial news for FPRX dated on 2018-09-12: Stocks Which Set New 52-Week Low Yesterday, September 11th

Financial news for FPRX dated on 2018-09-11: Seeing Notable Block Trade In Five Prime Therapeutics Of 1.1M Shares At \$12.80 Above The Ask Of \$12.73

Financial news for FPRX dated on 2018-09-10: Five Prime Therapeutics Completes Phase 1 Safety Lead-IN And Begins Phase 3 Trial, Expects TO Submit Phase 1 Lead-In Data For Presentation At Medical Conf. In First Half 2019

Financial news for FPRX dated on 2018-08-20: 10 Biggest Price Target Changes For Monday

Financial news for FPRX dated on 2018-08-20: Citigroup Maintains Buy on Five Prime Therapeutics, Lowers Price Target to \$44

Financial news for FPRX dated on 2018-08-17: Stocks Which Set New 52-Week Low Yesterday, August 16th

Financial news for FPRX dated on 2018-08-16: Stocks Which Set New 52-Week Low Yesterday, August 15th

Financial news for FPRX dated on 2018-08-16: The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

Financial news for FPRX dated on 2018-08-15: Stocks Which Set New 52-Week Low Yesterday, August 14th

Financial news for FPRX dated on 2018-08-15: The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

Financial news for FPRX dated on 2018-08-10: Stocks Which Set New 52-Week Low Yesterday, August 9th

Financial news for FPRX dated on 2018-08-08: Five Prime Therapeutics Q2 EPS \$(0.99) Beats \$(1.29) Estimate, Sales \$7.58M Miss \$10.34M Estimate

Financial news for FPRX dated on 2018-07-31: Stocks Which Set New 52-Week Low Yesterday, July 30th

Financial news for FPRX dated on 2018-07-30: Stocks Which Set New 52-Week Low Friday, July 27

Financial news for FPRX dated on 2018-06-29: Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

Financial news for FPRX dated on 2018-06-28: Raymond James Initiates Coverage On Five Prime Therapeutics with Market Perform Rating

Financial news for FPRX dated on 2018-06-15: Benzinga's Top Upgrades, Downgrades For June 15, 2018

Financial news for FPRX dated on 2018-06-15: JP Morgan Initiates Coverage On Five Prime Therapeutics with Neutral Rating, Announces \$19 Price Target

Financial news for FPRX dated on 2018-06-14: Apexigen, Yale Cancer Center Report Clinical Collaboration To Evaluate APX005M, Cabiralizumab, Opdivo In Patients Whose Disease Has Progressed On Anti-PD-1/PD-L1 Therapy

Financial news for FPRX dated on 2018-06-07: Jefferies 2018 Global Healthcare Conference Continues Today, Presenters Include: bluebird bio, GlycoMimetics, Five Prime Therapeutics, GTx, ImmunoGen, Puma Biotech, and Deciphera Pharma

Financial news for FPRX dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for FPRX dated on 2018-06-03: Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster at #ASCO2018

Financial news for FPRX dated on 2018-05-31: Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time

Financial news for FPRX dated on 2018-05-30: Five Prime Therapeutics Reports Collaboration Deal With Roche For Development Of Companion Diagnostics For Targeted Immuno-Oncology Investigational Drug Candidates

Financial news for FPRX dated on 2018-05-17: Wedbush Initiates Coverage On Five Prime Therapeutics With Neutral Rating, \$17 Price Target

Financial news for FPRX dated on 2018-05-15: Five Prime Therapeutics Names Bryan Irving Chief Scientific Officer

Financial news for FPRX dated on 2018-05-10: Benzinga's Top Upgrades, Downgrades For May 10, 2018

Financial news for FPRX dated on 2018-05-10: Goldman Sachs Initiates Coverage On Five Prime Therapeutics with Neutral Rating, Announces \$20 Price Target

Financial news for FPRX dated on 2018-05-08: Five Prime Therapeutics Q1 EPS \$(0.63) Misses \$(0.55) Estimate, Sales \$32.486M Beat \$27.62M Estimate

Financial news for FPRX dated on 2018-04-17: Five Prime Therapeutics 8-K Shows Linda Rubinstein Named Interim CFO

Financial news for FPRX dated on 2018-04-15: Five Prime Presents on Novel B7-H4 Therapeutic Antibody at #AACR18

Financial news for FPRX dated on 2018-04-10: 8-K From Five Prime Therapeutics Reports Co. Has Decided To Close Bladder Cancer Cohort Of Phase 1 FPA144 Trial

Financial news for FPRX dated on 2018-04-03: Personal Genome Diagnostics Reports Partnership to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics' Targeted Immuno-Oncology Drug Candidate Bemarituzumab; Financial Terms Not Disclosed

Financial news for FPRX dated on 2018-03-28: Five Prime Therapeutics Reports Initiation Of Patient Dosing In Phase 1 Trial Of FPA150

Financial news for FPRX dated on 2018-03-19: Five Prime Therapeutics Reports UCB Elected To Exclusively License Undisclosed Drug Target For Inflammatory Diseases

Financial news for FPRX dated on 2018-03-13: Five Prime Therapeutics CFO Marc Belsky Has Resigned

Financial news for FPRX dated on 2018-03-01: 50 Biggest Movers From Yesterday

Financial news for FPRX dated on 2018-02-28: BMO Capital Maintains Outperform on Five Prime Therapeutics, Lowers Price Target to \$60.00

Financial news for FPRX dated on 2018-02-28: Nomura Maintains Buy on Five Prime Therapeutics, Lowers Price Target to \$25.00

Financial news for FPRX dated on 2018-02-27: Five Prime Sees FY18 Net Cash Used In Operating Activities Less Than \$135M; Sees Ending '18 With ~\$250M In Cash

Financial news for FPRX dated on 2018-02-27: Five Prime Therapeutics Reports Q4 EPS \$(1.04) vs \$(1.31) Est., Sales \$13.2M vs \$15.5M Est.

Financial news for FPRX dated on 2018-01-25: Five Prime Therapeutics Receives \$25M Milestone Payment From Bristol-Myers

Financial news for FPRX dated on 2018-01-25: Five Prime Therapeutics Prices 5.128M Share Offering At \$19.50/Share

Financial news for FPRX dated on 2018-01-25: 42 Biggest Movers From Yesterday

Financial news for FPRX dated on 2018-01-24: Five Prime Therapeutics Shares Down 9.65% After Tuesday Announces Common Stock Offering, No Pricing Announced Yet

Financial news for FPRX dated on 2018-01-23: Five Prime Announces \$75M Common Stock Offering

Financial news for FPRX dated on 2018-01-08: UPDATE: Five Prime Says Is Eligible To Receive Up To \$300M In Future Development, Regulatory, Sales-Based Milestone Payments

Financial news for FPRX dated on 2018-01-08: UPDATE: Five Prime Says Bristol Extended Research Term Of Collaboration Deal With Co. For Second Time

Financial news for FPRX dated on 2018-01-08: Five Prime Therapeutics Reports Earned IND Milestone Payment Of \$5M Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb

Financial news for FPRX dated on 2018-01-03: Five Prime Therapeutics Submits IND For FPA150, Expects To Initiate Phase 1 Trial In 1H18

Financial news for FPRX dated on 2018-01-02: Five Prime Therapeutics Initiates Patient Dosing In PHase 1 Lead-In To Phase 3 Trial of FPA144

Financial news for FPRX dated on 2017-12-19: Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreement For FPA144 Anti-FGFR2b

Financial news for FPRX dated on 2017-11-09: Bristol-Myers Squibb, Five Prime Report Phase 1a/1b Data Evaluating Cabiralizumab With Opdivo In Patients With Advanced Solid Tumors

Financial news for FPRX dated on 2017-11-09: 57 Biggest Movers From Yesterday

Financial news for FPRX dated on 2017-11-08: 46 Stocks Moving In Wednesday's Mid-Day Session

Financial news for FPRX dated on 2017-11-08: 32 Stocks Moving In Wednesday's Pre-Market Session

Financial news for FPRX dated on 2017-11-08: 56 Biggest Movers From Yesterday

Financial news for FPRX dated on 2017-11-07: 45 Stocks Moving In Tuesday's Mid-Day Session

Financial news for FPRX dated on 2017-11-07: Mid-Day Market Update: U.S. Stocks Turn Lower; Kindred Healthcare Shares Rise After Q3 Results

Financial news for FPRX dated on 2017-11-07: Five Prime Therapeutics Shares Down 40.5% For Session, But Off Intraday Lows; Hearing Wells Fargo Recently Issued Comments Defending Co./Stock

Financial news for FPRX dated on 2017-11-07: Mid-Morning Market Update: Markets Mostly Higher; Dean Foods Misses Q3 Views

Financial news for FPRX dated on 2017-10-23: Five Prime Therapeutics Selects Aron Knickerbocker To Succeed Dr. Lewis Williams As President And CEO Effective Jan. 1st

Financial news for FPRX dated on 2017-10-17: 35 Biggest Movers From Yesterday

Financial news for FPRX dated on 2017-10-16: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for FPRX dated on 2017-10-16: Benzinga's Top Upgrades, Downgrades For October 16, 2017

Financial news for FPRX dated on 2017-10-16: BMO Capital Upgrades Five Prime Therapeutics to Outperform

Financial news for FPRX dated on 2017-10-11: 9 Stocks Moving In Wednesday's After-Hours Session

Financial news for FPRX dated on 2017-10-11: Five Prime Therapeutics Reports Phase 1a/1b Data Abstract For Cabiralizumab Selected For Late-Breaking Oral Presentation At SITC Meeting

Financial news for FPRX dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for FPRX dated on 2017-09-11: Array BioPharma And Others Shine At The ESMO 2017 Congress

Financial news for FPRX dated on 2017-09-10: Five Prime Therapeutics Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017

Financial news for FPRX dated on 2017-09-10: Five Prime Therapeutics Reports Encouraging Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017

Financial news for FPRX dated on 2017-09-01: Five Prime Reports Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039

Financial news for FPRX dated on 2017-08-08: Five Prime Therapeutics Reports Q2 EPS \$(1.58) vs \$(0.49) In Same Qtr. Last Year, Sales \$7.8M

Financial news for FPRX dated on 2017-07-17: Five Prime Therapeutics Reports Initiation Of Patient Dosing In Phase 1 Safety Trial Evaluating FPA114 In Gastric Cancer In Japan

Financial news for FPRX dated on 2017-06-21: Five Prime Therapeutics Reports CEO Rusty Williams To Transition To Chair In 2018

Financial news for FPRX dated on 2017-06-04: Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis #ASCO17

Financial news for FPRX dated on 2017-06-03: Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 #ASCO17

Financial news for FPRX dated on 2017-05-04: Five Prime Therapeutics Q1 EPS \$(1.21) vs \$(1.03) Est., Sales \$10.135M vs \$7.07M Est.

Financial news for FPRX dated on 2017-04-10: Five Prime Therapeutics Reports Closing of Enrollment for Phase 2 Part of Ongoing Trial of Cabiralizumab for Treatment of PVNS

Financial news for FPRX dated on 2017-04-02: Five Prime Presents Preclinical Research Data on Novel Tetravalent Anti-GITR Antibody at AACR 2017

Financial news for FPRX dated on 2017-03-24: Five Prime Therapeutics Up 0.63% After Earlier Cowen & Co. Initiation With Outperform

Financial news for FPRX dated on 2017-03-20: Five Prime Therapeutics Appoints Helen Collins Chief Medical Officer

Financial news for FPRX dated on 2017-03-02: Nomura Initiates Coverage On Five Prime Therapeutics at Buy

Financial news for FPRX dated on 2017-02-23: Five Prime Reports Q4 EPS \$(0.73) vs \$(0.57) Est., Sales \$8.262M vs \$7.09M Est.

Financial news for FPRX dated on 2017-02-08: Five Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting

Financial news for FPRX dated on 2017-01-24: Five Prime Therapeutics Reports European Commission Grants Orphan Drug Designation To Cabiralizumab

Financial news for FPRX dated on 2017-01-04: Five Prime Therapeutics, Bristol-Myers Squibb Extend Research Term in Partner to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways

Financial news for FPRX dated on 2016-12-01: Five Prime Presents Data Indicating FPA144 As A Treatment For Both Gastric And Bladder Cancer

Financial news for FPRX dated on 2016-11-03: Five Prime Reports Q3 EPS \$(0.72) vs. Est. \$(0.51)

Financial news for FPRX dated on 2016-10-25: Citi Launches Positive Coverage On Five Prime Therapeutics

Financial news for FPRX dated on 2016-10-25: Citigroup Initiates Coverage On Five Prime Therapeutics, Inc. - Common Stock at Buy, Announces \$65.00

Financial news for FPRX dated on 2016-10-04: Five Prime Therapeutics Reports Advancement Into Phase 1b Portion of Trial Evaluating Combo of FPA008, OPDIVO in Multiple Tumor Types

Financial news for FPRX dated on 2016-08-08: Monday's Market Wrap: Stocks Begin Week With Minor Losses

Financial news for FPRX dated on 2016-08-08: A Handful of Biotech Stocks Plunge After Disappointing Results

Financial news for FPRX dated on 2016-08-05: Five Prime Therapeutics Spikes to High of \$53.39 on Vol

Financial news for FPRX dated on 2016-08-04: Five Prime Therapeutics Reports Q2 EPS \$(0.49) vs. Est. \$(0.56), Rev. \$9.22M vs. Est. \$6.38M

Financial news for FPRX dated on 2016-07-14: GSK Exclusively Licenses Intellectual Property for Respiratory Disease Target Identified Using Five Prime's Proprietary Protein Discovery Platform, Triggering A \$1.5M License Payment To Five Prime

Financial news for FPRX dated on 2016-07-05: Five Prime Therapeutics' FPA144 Receives FDA Orphan Drug Status

Financial news for FPRX dated on 2016-07-05: Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA144 for the Treatment of Gastric Cancer

Financial news for FPRX dated on 2016-06-27: Five Prime Therapeutics To Collaborate With the University of Minnesota On a Protein Discovery Platform

Financial news for FPRX dated on 2016-06-06: GSK Informed FivePrime that FDA had Imposed Partial Clinical hold on GSK's Phase 1b Trial of FP-1039/GSK3052230

Financial news for FPRX dated on 2016-06-04: Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at #ASCO16

Financial news for FPRX dated on 2016-06-01: Five Prime Therapeutics Names Dr. Robert Sikorski as Chief Medical Officer

Financial news for FPRX dated on 2016-05-12: Five Prime Reports Advancement of FPA0008 into Phase 2 Dose Expansion in Patients with PVNS

Financial news for FPRX dated on 2016-05-05: Five Prime Therapeutics Reports Q1 EPS \$(0.49) Vs Est \$(0.71), Sales \$6.52M Vs Est \$5.26M

Financial news for FPRX dated on 2016-04-21: Director Berger Buys 6,090 Shares of Five Prime Therapeutics @\$47.06/Share -Form 4

Financial news for FPRX dated on 2016-04-20: 2 Winners From AACR Flying Under The Radar

Financial news for FPRX dated on 2016-04-12: BMO Capital Initiates Coverage on Five Prime Therapeutics at Market Perform, Announces \$50.00 PT

Financial news for FPRX dated on 2016-04-11: Five Prime Therapeutics Announces TRC105 Will Be Featured During Special Session at AACR Meeting

Financial news for FPRX dated on 2016-03-16: Five Prime Therapeutics Reports New Pre-Clinical Data on FPA144 at AACR Meeting: Enhanced Activity May Play Important Mechanistic Role in Anti-Tumor Efficacy

Financial news for FPRX dated on 2016-03-11: Credit Suisse Maintains Outperform on

Five Prime Therapeutics, Lowers PT to \$52.00

Financial news for FPRX dated on 2016-03-11: Credit Suisse Maintains Outperform on Five Prime Therapeutics, Lowers PT to \$52.00

Financial news for FPRX dated on 2016-03-10: Five Prime Reports Q4 EPS \$10.63 vs \$(0.55) in Same Qtr. Last Year, Sales \$363.341M vs \$4.645M YoY

Financial news for FPRX dated on 2016-03-10: Earnings Scheduled For March 10, 2016

Financial news for FPRX dated on 2016-02-01: Five Prime Therapeutics Appoints Kevin Baker As SVP Development Sciences

Financial news for FPRX dated on 2016-01-21: Five Prime Therapeutics Releases Prelim Data Regarding Dose Escalation Portion Of Phase 1 Trial FPA144; Says Well tolerated

Financial news for FPRX dated on 2016-01-20: Credit Suisse Initiates Coverage on Five Prime Therapeutics at Outperform, Announces \$54.00 PT

Financial news for FPRX dated on 2016-01-13: Five Prime Therapeutics Receives Orphan Drug Designation For FPA008

Financial news for FPRX dated on 2016-01-05: Five Prime Therapeutics Names Prominent Immuno-Oncology Thought Leaders to Scientific Advisory Board

Financial news for FPRX dated on 2015-11-19: Five Prime Therapeutics Begins Dose Expansion in Gastric Cancer Patients With FGFR2b Over-Expression in Phase 1 Trial of FPA144

Financial news for FPRX dated on 2015-11-19: Five Prime Therapeutics Start Dose Expansion in Gastric Cancer Patients With FGFR2b Over-Expression in Phase 1 Trial of FPA144

Financial news for FPRX dated on 2015-11-11: US Stock Futures Gain Ahead Of Macy's Earnings

Financial news for FPRX dated on 2015-11-11: Five Prime Therapeutics Receives Early HSR Clearance for FPA008 License, Collaboration Agreement With Bristol-Myers Squibb

Financial news for FPRX dated on 2015-11-04: Five Prime Therapeutics Reports Q3 EPS \$(0.93) vs \$(0.99) Est., Sales \$5.9M vs \$4.9M Est.

Financial news for FPRX dated on 2015-10-19: How Five Prime's Bristol-Myers Partnership Helps Investors

Financial news for FPRX dated on 2015-10-15: Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results

Financial news for FPRX dated on 2015-10-15: Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics Shares Spike Higher

Financial news for FPRX dated on 2015-10-15: Benzinga's Volume Movers

Financial news for FPRX dated on 2015-10-15: Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops Estimates

Financial news for FPRX dated on 2015-10-15: Morning Market Gainers

Financial news for FPRX dated on 2015-10-15: Benzinga's Top #PreMarket Gainers

Financial news for FPRX dated on 2015-10-15: Five Prime Therapeutics +68% Premarket Following Announcement of Worldwide License, Collaboration Agreement on CSF1R Antibody Program With Bristol-Myers Squibb

Financial news for FPRX dated on 2015-10-15: Bristol-Myers Squibb, Five Prime Therapeutics Announce Worldwide License, Collaboration Agreement on CSF1R Antibody Program

Financial news for FPRX dated on 2015-10-15: Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program

Financial news for FPRX dated on 2015-10-07: Five Prime Therapeutics Announces The Presentation of Preliminary FPA008 Phase 1 Trial Data in Rheumatoid Arthritis Patients at the 2015 ACR Annual Meeting

Financial news for FPRX dated on 2015-09-10: US Stock Futures Rise Ahead Of Jobless Claims, Wholesale Inventories Data

Financial news for FPRX dated on 2015-09-10: Five Prime Therapeutics Announces Initial Data From Ongoing Phase 1b Trial of FP-1039 in Squamous NSCLC, Mesothelioma

Financial news for FPRX dated on 2015-09-08: Five Prime Therapeutics Begins Patient Dosing in Phase 1a/1b Trial Evaluating the Immunotherapy Combination of FPA008 and OPDIVO in Six Tumor Types

Financial news for FPRX dated on 2015-08-24: Five Prime Therapeutics Announces Oral Presentation of Initial Data From Ongoing Phase 1b Trial of FP-1039/GSK3052230 in Squamous Non Small Cell Lung Cancer and Mesothelioma at World Conference on Lung Cancer

Financial news for FPRX dated on 2015-08-06: Five Prime Therapeutics Reports Q2 Loss \$0.45 Vs Est Loss \$0.44

Financial news for FPRX dated on 2015-08-06: Five Prime Therapeutics Reports Q2 Loss of \$0.45/Share vs Loss of \$0.44/Share Est.

Financial news for FPRX dated on 2015-07-31: Benzinga's Top Initiations

Financial news for FPRX dated on 2015-07-31: Citigroup Initiates Coverage on Five Prime Therapeutics at Buy, Announces \$33.00 PT

Financial news for FPRX dated on 2015-07-15: Five Prime Therapeutics Establishes Strategic Research Collaboration and License Agreement With Inhibrx for Novel GITR Antibodies

Financial news for FPRX dated on 2015-07-13: Five Prime Therapeutics Begins Patient Dosing in Phase 1/2 Clinical Trial Evaluating FPA008 in Pigmented Villonodular Synovitis

Financial news for FPRX dated on 2015-05-28: BMO Capital: Five Prime Therapeutics Still A Buy, Worth \$31/Share Now

Financial news for FPRX dated on 2015-05-27: Morning Market Gainers

Financial news for FPRX dated on 2015-05-27: Benzinga's Top #PreMarket Gainers

Financial news for FPRX dated on 2015-05-26: Five Prime Therapeutics, TiVo, ITT Educational Services Lead Tuesday's After-Hours Movers

Financial news for FPRX dated on 2015-05-26: Five Prime Therapeutics Shares Rise 17% After-Hours Following Announcement of Deal With Bluebird Bio

Financial news for FPRX dated on 2015-05-26: bluebird bio, Five Prime Therapeutics Enter Exclusive License Agreement For Novel Antibodies To Develop Chimeric Antigen Receptor T Cell Therapy

Financial news for FPRX dated on 2015-05-15: Oppenheimer: Buy Five Prime Therapeutics, It's Worth \$45/Share

Financial news for FPRX dated on 2015-05-13: S-3 from Five Prime Therapeutics Shows Registration for \$200M Common Stock Shelf Offering

Financial news for FPRX dated on 2015-05-13: Benzinga's Top Initiations

Financial news for FPRX dated on 2015-05-13: Guggenheim Securities Initiates Five Prime Therapeutics With Buy

Financial news for FPRX dated on 2015-05-13: Guggenheim Securities Initiates Coverage on Five Prime Therapeutics at Buy, Announces \$31.00 PT

Financial news for FPRX dated on 2015-04-07: Regulus Therapeutics, Healthcare Stocks Are Big Movers In Tuesday's After Hours Trading

Financial news for FPRX dated on 2015-04-06: Must Watch Stocks for Today

Financial news for FPRX dated on 2015-04-02: Bind Therapeutics Inc, Noble Energy, Inc., Others Are Moving After-Hours

Financial news for FPRX dated on 2015-03-19: Vaccinex, Five Prime Therapeutics Sign Multi-Target Antibody Discovery Deal Press Release

Financial news for FPRX dated on 2015-03-19: Vaccinex, Five Prime Therapeutics Sign Multi-Target Antibody Discovery Deal

Financial news for FPRX dated on 2015-03-17: Tuesday's After-Hours Movers: Oracle, Papa Murphy's And More

Financial news for FPRX dated on 2015-03-17: Five Prime Therapeutics REports Q4 EPS \$(0.55) vs. Est. \$(0.10), Rev. \$4.6M vs. Est. \$12.4M; Estimates May Not Compare

Financial news for FPRX dated on 2015-02-02: Microsoft, Bank Of New York And Others Insiders Have Been Buying

Financial news for FPRX dated on 2015-01-29: Five Prime Therapeutics Director Berger Buys 25,000 Shares @\$27.03/Share -Form 4

Financial news for FPRX dated on 2015-01-23: Hedge Fund Takes 5% Passive Stake In Five Prime Therapeutics

Financial news for FPRX dated on 2015-01-23: 13G: Steven Cohen Reports 5% Stake In Five Prime Therapeutics

Financial news for FPRX dated on 2015-01-23: UPDATE: Leerink Partners Initiates Coverage On Five Prime Therapeutics On Multiple Value Drivers

Financial news for FPRX dated on 2015-01-23: Leerink Swann Initiates Coverage on Five Prime Therapeutics at Outperform, Announces \$35.00 PT

Financial news for FPRX dated on 2015-01-22: Leerink Initiates Coverage On Five Prime Therapeutics

Financial news for FPRX dated on 2015-01-15: 13D Filing from Adage Capital Partners on Five Prime Therapeutics Shows Increased Stake from 2% as of Sept. 30 to 6.09%

Financial news for FPRX dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Financial news for FPRX dated on 2015-01-07: 4 More Biotech Secondaries Investors Are Watching

Financial news for FPRX dated on 2015-01-07: Wednesday Morning Movers

Financial news for FPRX dated on 2015-01-07: Benzinga's Top #PreMarket Losers

Financial news for FPRX dated on 2015-01-06: Five Prime Therapeutics Prices 3.41M Share Offering @\$22.00/Share

Financial news for FPRX dated on 2015-01-06: 4 Biotech Secondary Offerings Traders Are Watching

Financial news for FPRX dated on 2015-01-06: Morning Market Losers

Financial news for FPRX dated on 2015-01-06: Keep an Eye on These 7 Stocks for January 6, 2015

Financial news for FPRX dated on 2015-01-05: Monday's After-Hours Market Movers

Financial news for FPRX dated on 2015-01-05: Five Prime Announces \$75M Proposed Public Offering of Common Stock

Financial news for FPRX dated on 2015-01-05: Five Prime Reports \$75M Proposed Stock Offering

Financial news for FPRX dated on 2014-12-04: Five Prime Therapeutics Initiates Patient Dosing In Phase 1 Clinical Trial Evaluating FPA144

Financial news for FPRX dated on 2014-12-03: Filing from Five Prime Therapeutics Shows Registration for \$100M Mixed Securities Shelf Offering

Financial news for FPRX dated on 2014-11-24: Mid-Day Gainers From November 24: Prosensa, Cimatron, Platinum Underwriters, Five Prime Therapeutics, Tetrphase Pharmaceuticals

Financial news for FPRX dated on 2014-11-24: Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration

Financial news for FPRX dated on 2014-11-17: Five Prime Therapeutics Reports Commencement of Dosing of RA Patients in Phase 1 Trial of FPA008

Financial news for FPRX dated on 2014-11-13: Five Prime Therapeutics to Present Data From Healthy Volunteer Cohorts in Phase 1 Trial of FPA008 at the 2014 ACR/ARHP Annual Scientific Meeting

Financial news for FPRX dated on 2014-11-10: S-3 from Five Prime Therapeutics Shows Registration for \$100M Common Stock Shelf Offering

Financial news for FPRX dated on 2014-09-15: Five Prime Therapeutics Announces Option Exercise by GlaxoSmithKline For A Commercial License To A Novel Muscle Disease Target

Financial news for FPRX dated on 2014-05-08: Five Prime Therapeutics Reports Q1 EPS of \$(0.46) vs \$(0.05) Est; Revenue of \$3.55M vs \$10.54M Est

Financial news for FPRX dated on 2014-03-25: Five Prime Therapeutics Reports Q1 EPS of \$(0.43) vs \$(0.40) Est; Revenue of \$3.79M vs \$3.83M Est

Financial news for FPRX dated on 2014-03-17: Market Wrap For March 17: Investors Focused On Economic Data Instead Of Crimea Concerns

Financial news for FPRX dated on 2014-03-17: US Stock Futures Jump Ahead Of Economic Data

Financial news for FPRX dated on 2014-03-17: Five Prime Therapeutics, Bristol-Myers Squibb Announce Collaboration Agreement

Financial news for FPRX dated on 2014-03-14: Five Prime Therapeutics In Late-Stage Negotiations With Third Party With Respect To Cancer Immunotherapy Discovery Collaboration -Filing

Financial news for FPRX dated on 2014-02-07: US Stock Futures Up; All Eyes On Jobs Report

Financial news for FPRX dated on 2014-02-07: Five Prime Therapeutics Prices 3M Share Offering at \$12.50/Share

Financial news for FPRX dated on 2014-02-03: Five Prime Therapeutics Offering 3M Shares at \$57.5M Maximum Offering Price

Financial news for FPRX dated on 2014-01-22: Five Prime Therapeutics Files to Offer \$50M in Common Shares

Financial news for FPRX dated on 2013-10-23: Five Prime Therapeutics Appoints Aron Knickerbocker to Its Board of Directors and Marc Belsky to Chief Financial Officer

Financial news for FPRX dated on 2013-10-14: UPDATE: Jefferies Initiates Coverage on Five Prime Therapeutics on Attractive Risk/Reward Profile

Financial news for FPRX dated on 2013-10-14: Benzinga's Top Initiations

Financial news for FPRX dated on 2013-10-14: Guggenheim Securities Initiates Coverage on Five Prime Therapeutics at Buy, Announces \$20.00 PT

Financial news for FPRX dated on 2013-10-14: Wells Fargo Initiates Coverage on Five Prime Therapeutics at Outperform

Financial news for FPRX dated on 2013-10-14: BMO Capital Initiates Coverage on Five Prime Therapeutics at Outperform, Announces \$24.00 PT

Financial news for FPRX dated on 2013-10-14: Jefferies Initiates Coverage on Five Prime Therapeutics at Buy, Announces \$20.00 PT

Financial news for FPRX dated on 2013-09-26: Five Prime Announces the Exercise of the Underwriters' Over-Allotment Option for 720K Additional Shares

Financial news for FPRX dated on 2013-09-18: Shares of Five Prime Therapeutics Open for Trade at \$16, Priced at \$13

Financial news for FPRX dated on 2013-09-18: IPO for Shares of Five Prime Therapeutics Now Open for Quote, Expected to Open for Trade at 10:40AM EDT

Financial news for FPRX dated on 2013-09-17: Five Prime Therapeutics Prices 4.8M Share IPO at \$13.00/Share

Financial news for FPRX dated on 2013-09-04: Five Prime Therapeutics Expecting IPO of 4M Shares in \$12-14/Share Range, Will List on NASDAQ